Literature DB >> 21482894

The use of B vitamins for cutaneous ulcerations mimicking pyoderma gangrenosum in patients with MTHFR polymorphism.

Douglas New1, Philip Eaton, Al Knable, Jeffrey P Callen.   

Abstract

BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) polymorphisms are associated with thrombophilia and vasculopathy that may result in cutaneous ulceration. Pyoderma gangrenosum (PG) is a clinical diagnosis that may be made following exclusion of alternate causes of ulceration, including vascular inflammatory or occlusive disease, infection, and malignant neoplasm. OBSERVATIONS: We describe 2 patients with MTHFR polymorphisms discovered during hypercoagulable evaluation for cutaneous ulcerations on the lower extremities. Both patients showed a rapid improvement following treatment with oral vitamin supplementation and local wound care. One patient developed several subsequent ulcers when he decided to discontinue his therapy, and following reinitiation of therapy, the new ulcerations healed. The treatment was tolerated well without any adverse effects.
CONCLUSIONS: MTHFR polymorphisms should be part of a comprehensive laboratory evaluation during hypercoagulable workup. Vitamin supplementation with folic acid (B(9)), pyridoxine hydrochloride (B(6)), and cyanocobalamin (B(12)) may result in healing of cutaneous ulcerations in some patients with MTHFR mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482894     DOI: 10.1001/archdermatol.2011.77

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  2 in total

1.  Pyoderma gangrenosum-like lesion secondary to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease.

Authors:  Yana Turkowski; Syed Razvi; Abdul Razzaque Ahmed
Journal:  BMJ Case Rep       Date:  2019-04-23

2.  Association of MTHFR gene C677T mutation with recurrent aphthous stomatitis and number of oral ulcers.

Authors:  Goknur Kalkan; Nevin Karakus; Serbulent Yigit
Journal:  Clin Oral Investig       Date:  2013-05-11       Impact factor: 3.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.